We use cookies to improve your experience on our site and to analyze traffic. By clicking "Accept", you consent to our use of cookies. Learn more.

Nova In Silico will be at ACoP 2026Meet the team and see our programDetails here
Back to Case Studies
·October 28, 2022

Atopic dermatitis

Nova has built a mechanistic model of AD representing the interplay between the skin barrier and the immune system in a pediatric population.

Download PDF

Atopic dermatitis case study

Atopic dermatitis (AD) is characterized by a complex pathophysiology with a wide spectrum of phenotypes. This high diversity makes mechanistic in silico approaches particularly adapted for guiding clinical development. In the context of the bacterial lysate OM-85’s development to treat atopic dermatitis, OM Pharma wanted to conduct an in silico exploration of the immune mechanisms driving the treatment response in order to characterize the best responders. Nova has built a mechanistic model of AD representing the interplay between the skin barrier and the immune system in a pediatric population.